United Therapeutics (UTHR) Stock Price, News & Analysis

Company Overview

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs. In addition to its PAH portfolio, United Therapeutics markets dinutuximab (Unituxin) for high-risk neuroblastoma and continues to expand its therapeutic reach through ongoing clinical programs.

Founded in 1996 and headquartered in Silver Spring, Maryland, United Therapeutics has combined its core expertise in vascular biology with innovative manufacturing technologies. Beyond pharmaceuticals, the company’s Lung Biotechnology PBC subsidiary explores regenerative medicine approaches, including decellularized and recellularized organ scaffolds and xenotransplantation methods aimed at addressing organ shortages. Its research pipeline encompasses next-generation agents for PAH, oncology, and transplant applications, reflecting a broad commitment to extending and improving life for patients with complex diseases.

United Therapeutics operates globally, with commercial and clinical efforts spanning North America, Europe, and Asia. Its international infrastructure supports regulatory submissions and patient access programs in key markets such as the European Union and Japan. Under the leadership of founder and Chief Executive Officer Martine Rothblatt, the company emphasizes a multidisciplinary culture that integrates basic science, engineering and patient advocacy. This approach drives its mission to pioneer transformational therapies and sustainable organ manufacturing technologies for conditions with high unmet medical need.

Key Stats

• Today's Range: $419.54 to $436.00
• 50-Day Range: $301.39 to $456.84
• 52-Week Range: $266.98 to $459.48
• Volume: 645,022 shs
• Average Volume: 761,551 shs
• Market Capitalization: $19.52 billion
• P/E Ratio: 16.89
• Dividend Yield: N/A
• Price Target: $457.21
• Consensus Rating: Moderate Buy

United Therapeutics Stock Analysis - MarketRank™

United Therapeutics scored higher than 95% of companies evaluated by MarketBeat, and ranked 56th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

United Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 10 buy ratings, 4 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for United Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

United Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.30%

Earnings Growth

Earnings for United Therapeutics are expected to grow by 12.30% in the coming year, from $24.48 to $27.49 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of United Therapeutics is 16.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 43.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of United Therapeutics is 16.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.47.

Price to Earnings Growth Ratio

United Therapeutics has a PEG Ratio of 4.72. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

United Therapeutics has a P/B Ratio of 3.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.00% of the float of United Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

United Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in United Therapeutics has recently decreased by 21.22%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

United Therapeutics does not currently pay a dividend.

Dividend Growth

United Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -2.00

Percentage of Shares Shorted

5.00% of the float of United Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

United Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in United Therapeutics has recently decreased by 21.22%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.08

News Sentiment

United Therapeutics has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for United Therapeutics this week, compared to 20 articles on an average week.

Search Interest

4 people have searched for UTHR on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

4 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $125,401,167.00 in company stock.

Percentage Held by Insiders

10.30% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

UTHR Stock Analysis - Frequently Asked Questions

How have UTHR shares performed this year?

United Therapeutics' stock was trading at $352.84 at the beginning of the year. Since then, UTHR shares have increased by 22.6% and is now trading at $432.69.

How were United Therapeutics' earnings last quarter?

United Therapeutics Corporation (NASDAQ:UTHR) announced its earnings results on Wednesday, July, 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by $0.39. The business's quarterly revenue was up 11.7% compared to the same quarter last year.
Read the conference call transcript.

Who are United Therapeutics' major shareholders?

Top institutional investors of United Therapeutics include Pacer Advisors Inc. (0.75%), Swedbank AB (0.73%), Allspring Global Investments Holdings LLC (0.20%) and Wedge Capital Management L L P NC (0.15%). Insiders that own company stock include Paul A Mahon, Richard Giltner, Tommy G Thompson, James Edgemond, Louis W Sullivan, Judy D Olian, Nilda Mesa, Christopher Causey, Raymond Dwek, Jan Malcolm, Martine A Rothblatt, Michael Benkowitz and Christopher Patusky.
View institutional ownership trends.

How do I buy shares of United Therapeutics?

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 7/30/2025
• Today: 10/20/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:UTHR
• CIK: 1082554
• Web: www.unither.com
• Phone: (301) 608-9292
• Fax: 301-608-9291
• Employees: 1,305
• Year Founded: 1996

Price Target and Rating

• Average Price Target for United Therapeutics: $457.21
• High Price Target: $580.00
• Low Price Target: $302.00
• Potential Upside/Downside: +5.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $25.62
• Trailing P/E Ratio: 16.89
• Forward P/E Ratio: 17.68
• P/E Growth: 4.72
• Net Income: $1.20 billion
• Net Margins: 40.36%
• Pretax Margin: 52.54%
• Return on Equity: 18.73%
• Return on Assets: 16.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.26
• Quick Ratio: 6.94

Sales & Book Value

• Annual Sales: $2.88 billion
• Price / Sales: 6.78
• Cash Flow: $28.35 per share
• Price / Cash Flow: 15.26
• Book Value: $144.34 per share
• Price / Book: 3.00

Miscellaneous

• Outstanding Shares: 45,110,000
• Free Float: 40,461,000
• Market Cap: $19.52 billion
• Optionable: Optionable
• Beta: 0.66